Does Rallies show Form 4 insider transactions for DERM?

Yes. Rallies tracks DERM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is DERM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DERM. It does not provide personalized investment advice.

DERM (Journey Medical Corporation Common Stock) Stock Analysis - Insider Trades

Journey Medical Corporation Common Stock (DERM) is a publicly traded Healthcare sector company. As of May 21, 2026, DERM trades at $6.17 with a market cap of $172.09M and a P/E ratio of -16.63. DERM moved +0.08% today. Year to date, DERM is -13.34%; over the trailing twelve months it is -10.32%. Its 52-week range spans $3.54 to $9.56. Analyst consensus is strong buy with an average price target of $13.50. Rallies surfaces DERM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading DERM stock inside the company?

Recent DERM insider activity includes Maraoui Claude sold 4.83K, Benesch Joseph sold 2.41K, Alloush Ramsey sold 2.86K, Maraoui Claude sold 49.27K, and Maraoui Claude sold 14.90K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

DERM Key Metrics

Key financial metrics for DERM
Metric	Value
Price	$6.17
Market Cap	$172.09M
P/E Ratio	-16.63
EPS	$-0.37
Dividend Yield	0.00%
52-Week High	$9.56
52-Week Low	$3.54
Volume	0
Avg Volume	0
Revenue (TTM)	$64.68M
Net Income	$-9.59M
Gross Margin	65.44%

Recent DERM Insider Trades

Maraoui Claude sold 4.83K (~$33.06K) on May 2, 2025.
Benesch Joseph sold 2.41K (~$16.48K) on May 2, 2025.
Alloush Ramsey sold 2.86K (~$19.54K) on May 2, 2025.
Maraoui Claude sold 49.27K (~$246.85K) on Mar 11, 2025.
Maraoui Claude sold 14.90K (~$74.67K) on Mar 7, 2025.

Latest DERM News

Journey Medical Reports Q1 Loss Narrowing From $0.18, Revenue Tops Forecasts — May 14, 2026
Journey Medical Secures Third GPO Contract to Cover 150M Commercial Lives for Emrosi — Apr 21, 2026
Journey Medical Achieves 11% Product Revenue Growth, MROS Sales Hit $14.7M in Nine Months — Mar 26, 2026
Journey Medical Forecasts Q4 Revenue of $18.9M and 6¢ Loss Ahead of Earnings — Mar 24, 2026

DERM Analyst Consensus

4 analysts cover DERM: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.50.

Common questions about DERM

Who is trading DERM stock inside the company?: Recent DERM insider activity includes Maraoui Claude sold 4.83K, Benesch Joseph sold 2.41K, Alloush Ramsey sold 2.86K, Maraoui Claude sold 49.27K, and Maraoui Claude sold 14.90K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for DERM?: Yes. Rallies tracks DERM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is DERM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DERM. It does not provide personalized investment advice.